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Diabetic foot ulcerations are historically diﬃcult to treat despite advanced therapeutic modalities. There are numerous modalities
described in the literature ranging from noninvasive topical wound care to more invasive surgical procedures such as primary
closure, skin ﬂaps, and skin grafting. While skin grafting provides faster time to closure with a single treatment compared to
traditional topical wound treatments, the potential risks of donor site morbidity and poor wound healing unique to the diabetic
state have been cited as a contraindication to its widespread use. In order to garner clarity on this issue, a literature review was
undertaken on the use of split-thickness skin grafts on diabetic foot ulcers. Search of electronic databases yielded four studies that
reported split-thickness skin grafts as deﬁnitive means of closure. In addition, several other studies employed split-thickness skin
grafts as an adjunct to a treatment that was only partially successful or used to ﬁll in the donor site of another plastic surgery
technique. When used as the primary closure on optimized diabetic foot ulcerations, split-thickness skin grafts are 78% successful
at closing 90% of the wound by eight weeks.
1.Introduction
There are many means of treating diabetic ulcerations.
A conservative approach may entail regular debridement
and dressing changes. Topical solutions such as saline,
iodine, antimicrobial absorbent ﬁber sheets, and collagenase
ointments may be included. For wounds with macerated
edges it may be adventitious to apply gauze with diluted
iodine to prevent further maceration. In hyperkeratotic,
ﬁbrotic, or dry necrotic tissue borders, it is preferred to apply
hydrogels to hydrate the surrounding area. It is important
to debride ﬁbrotic wounds. This can be done mechanically
by applying saline wet to dry dressings, and then after the
dressing is changed, it removes ﬁbrotic tissue with it. Some
institutions employ the use of negative pressure wound
therapy (NPWT) to stimulate granulation tissue and help
remove ﬁbrotic tissue formation [1]. Also, NPWT is good
for draining wounds, along with calcium alginates which
help absorption. Collagenases can be used to chemically
debride wounds, and sharp debridement is a time tested
method to remove non-viable tissue. There are also several
bioengineered products that may facilitate wound closure
oncethewoundisinfection-freeandhasaprimarilygranular
base. These materials help deliver ﬁbroblasts to wounds and
help serve as a scaﬀold for new tissue growth. Sometimes
chronic wounds remain or the wound is deep with an
irregular contour, and plastic surgery techniques must be
employed such as skin grafts and ﬂaps. More advanced ﬂaps
are ideal for plantar or weight-bearing wounds because they
have more substance and contain their own blood or nerve
supply which increases graft take. These are also indicated in
wounds with avascular bases such as directly over tendons,
or bone without periosteum. Advanced techniques are
challenging at times and create a new wound or leave a large
donorsitedeﬁcit.This,onadiabeticpatientwithdiminished
healingpropertiesandincreasedsusceptibilitytoinfection,is
not ideal. Thus, if a ﬂap is not possible, split-thickness skin
graftsmaybethebettertreatmentoptiontoclosechallenging
wounds once a granular base is achieved.
Split-thickness skin grafting (STSG) is a plastic surgery
technique with documented use dating back to 3000 B.C.
in India for traumatic facial wounds [2]. Ollier began2 Plastic Surgery International
experimenting with skin grafting methods in 1872. An
electrodermatome was used to harvest STSG by Pagett &
Hood in 1939 [3]. Modern techniques involving the use
of meshed STSG was ﬁrst described in 1964 by Tanner et
al. [4]. Despite the original use for facial reconstruction,
STSG is now commonly employed on burn wounds, when
skin coverage is required, and to close chronic ulcerations,
frequently seen in the diabetic population. Recent literature
on burn patients has shown STSG to have a 96.7% graft take
in optimal conditions [5].
STSG in diabetic wounds poses several unique concerns
including the presence of neuropathy, endothelial dysfunc-
tion, and increased susceptibility to infection. Neuropathy is
a concern because the patients are not in pain and are often
unaware of the severity of their wound until the infection
spreads more proximally. Endothelial dysfunction disrupts
all vascular components especially the microvasculature seen
in eyes, kidneys, and distal extremities. Also, hyperglycemia
retards the chemotaxic response to ﬁght infection. These
systemic challenges, coupled with patient-speciﬁc obstacles
that all surgeons entertain, namely, tobacco history, poor
nutrition, and noncompliance, make the care of chronic
wounds challenging. As a result, many surgeons select
conservative care with regular dressing changes to treat
diabetic wounds. When this fails, it is best to choose a plastic
surgery modality that the surgeon is comfortable with and
has minimal morbidity to the patient. This procedure should
also be deﬁnitive and restore a healthy skin barrier. These
authors prefer to use STSG to close challenging wounds
because it causes little morbidity to the patient and its
documented success in burn patients [5]. When STSG is
utilized, the recipient wound bed needs to be granular taking
care to remove all infected tissue and optimizing the vascular
status prior to application. The purpose of this study was
to analyze the literature to determine the indications and
successofsplit-thickness skingraftsusedondiabetic wounds
and the reported risks and complications.
2.MaterialsandMethods
In an eﬀort to determine the eﬃcacy of this treatment, a
literature review was undertaken to evaluate the outcomes
of STSG in diabetic patients. These authors undertook a
systematic review of electronic databases, namely the U.S.
National Library of Medicine, National Institutes of Health-
PubMed.gov (http://www.ncbi.nlm.nih.gov/pubmed/), from
inception until 6/21/11. There was no restriction on data
or language, and an inclusive text word query for “Dia-
betes” AND “Split-Thickness Skin Graft” was entered, where
the upper-case words represented the Boolean operators
employed.
Forty articles were secured using this method. Following
this, the references from the original forty articles were
analyzed searching for the same inclusion criteria. After
review, twenty-two articles were yielded that described STSG
on diabetic patients. All articles pertained to lower-extremity
wounds,thoughthiswasnotdetailedintheinclusioncriteria
of the search. A meta-analysis was then undertaken to ﬁnd
commonalities amongst the articles. These authors deﬁned
“success” to be 90% epithelization of the STSG recipient site
by eight weeks using a single procedure with no infection or
reulceration at ﬁnal follow-up. Success rates were analyzed
from the results of the four primary articles that speciﬁcally
reviewed STSG on diabetic wounds [6–9].
3. Results and Discussion
Twenty-two articles were yielded from the initial search [6–
27], with four articles found speciﬁcally addressing STSG
on diabetic wounds [6–9]. These studies ranged from a case
presentation to a prospective, randomized controlled trial
and accounted for a total of 229 diabetic patients with lower-
extremity wounds.
Of the remaining eighteen articles, eight detailed tech-
niques on application of STSG, or as one possible treatment
option used on diabetic wounds [10–17]. Three articles used
bioengineered or advanced techniques (platelet-rich plasma)
in conjunction with STSG [18–20]. Three articles applied
STSG over a (gracilis muscle) free ﬂap or subcutaneous ﬂap
[21–23]. Two articles utilized STSG on top of a donor site to
an advanced plastic technique: reverse sural artery ﬂap and
medial plantar artery ﬂap [24, 25]. The last two employed
STSG to heal a partially closed wound treated with another
modality or to help close a burn site [26, 27].
The study purpose of the four articles describing STSG
on diabetic wounds varied, as depicted in Table 1 [6–9].
Ramanujam et al. [8] retrospectively examined the success
of STSG as a deﬁnitive treatment for wounds in patients with
diabetes while Mahmoud et al. [6] prospectively compared
the eﬀect on healing times of STSG versus conservative
wound dressing in the treatment of diabetic foot ulcers. The
remainingtwostudiesevaluatedtheinﬂuenceofmeshingthe
STSG[7]andtheuseof10%phenytoinointmentasawound
bed preparation [9] prior to STSG application.
The etiology and location of the diabetic ulcers also
varied signiﬁcantly between the four studies. Three out of
the four papers studied ulcers located on any area of the
foot, including the plantar aspect, heel, interdigital area, and
dorsum of the foot [6, 7, 9]. In addition to neuropathic
diabetic foot ulcers, Ramanujam et al. included foot and
ankle wounds stemming from traumatic, surgical, and
infectious origins. All studies pertained to lower-extremity
wounds and excluded an ulcer or wound with clinical signs
of infection. It is not recommended to apply a STSG over
infected tissue or exposed bone, tendon, or ligaments. This
was not excluded in the research presented, but using a STSG
over avascular tissues is contraindicated.
Mahmoud et al. studied the diﬀerence in days to heal and
days spent in the hospital in 100 diabetic patients (ﬁfty in
each group) using STSG versus conservative wound care [6].
All the patients in the study did heal completely; however,
the STSG group healed in an average of 28 days, versus 122
days in the conservative group. The mean hospital stay was
also decreased by twelve days. Puttirutvong et al. assessed
meshed versus nonmeshed skin grafts in eighty diabetic
patients [7]. There was no statistical diﬀerence betweenPlastic Surgery International 3
Table 1: Meta-analysis of STSG on diabetic wounds.
Lead author Study type Purpose Patients Follow-up %
success∗
Mahmoud
(Sudan)
Nonrandomized
case-controlled prospective
comparative
Determine the diﬀerence in
hospital days and days to heal
between STSG and conservative
care
50
(in each group)
1 year
(following closure) 86%
Puttirutvong
(Thailand)
Prospective randomized
controlled
Assess meshed versus
non-meshed skin grafts
80
(38 meshed)
6m o n t h s
(from application) 82.50%
Ramanujam
(USA)
Retrospective consecutive
review
Analyze STSG in diabetic
patients 83 >6m o n t h s
(from application) 65%
Younes
(Jordan) Case study
Determine the impact of
phenytoin ointment prior to
STSG application
16 FU not mentioned 93.75%
∗Success as determined by 90% graft epithelization by 8 wks with 1 procedure & no documented reulceration or infection to initial site at ﬁnal follow-up.
Abbreviations: STSG, split-thickness skin graft; FU, follow-up; wks, weeks.
the two groups, and again all patients in the study healed
completely. Ramanujam et al. retrospectively analyzed STSG
in 83 consecutive diabetic patients [8]. All of the patients
healed successfully by the ﬁnal follow-up, but this included
repeat surgical procedures or additional graft applications.
Younes et al. concluded that phenytoin ointment (originally
used orally as an anticonvulsant) prior to application of
STSG is safe and enhances the survival of the graft on sixteen
diabetic patients [9].
Despiteeacharticle’sdiﬀerentpurpose andpostoperative
protocol, a meta-analysis was performed and found a
similarity of STSG success. In Mahmoud’s article, it mention
that thirty-one patients had 100% graft take at week eight
in the discussion. However, it also states that 86% (forty-
three) patients had healed completely by week eight [6]. This
authorusedthegreaterhealing percentage(86%) inthetable
provided (Table 1), understanding that while graft take was
100%, only 86% healed by week eight. Puttirutvong used
STSG on all the study patients; however, the control group
consisted of 42 unmeshed grafts and 35 of these patients had
“good” to “excellent” healing [7]. “Excellent” was described
as skin grafts healed 95% within 2 weeks with a smooth
scar; “good” was skin graft healed 95% within 3 weeks and
a hypertrophic scar subsided within 6 months. The meshed
group consisted of 38 patients; 31 of these had “good” to
“excellent” healing. This oﬀered a combined 82.5% “good”
to “excellent” healing. Ramanujam’s retrospective review
showed65%ofpatientshealeduneventfully[8].Younes’case
studyrevealed15of16STSGpatientshad+90%healingwith
2–8 weeks of preparation with phenytoin [9]. Combining
these results in 229 patients, STSG is 78% successful, where
success is described as 90% graft epitheliazation with a single
procedure at eight weeks and no documented reulceration or
infection to the recipient site at ﬁnal follow-up.
The four primary articles in this review originated from
four diﬀerent countries [6–9]. Further analysis of the articles
showed that graft size, donor and recipient location, patient
age, gender, and race did not Eﬀect graft survival per
Ramanujam [8]. Most, (60%) of the patients in Mahmoud’s
study had a wound size between ﬁve and ten centimeters;
there was no mention of wound location, depth, diabetic
control, or vascular status [6]. Also, in the Puttirutvong
study: depth, location, diabetic control, & vascular status
were not addressed. The range of ulcer size was between
12cm2 to 600cm2 [7]. Younes only examined large ulcers,
described as >20cm2 [9]. It should also be noted that
the articles did not mention the patients lower-extremity
perfusion, which is an important factor of graft success,
along with a well-prepared wound bed. Also, most articles
failed to acknowledge the exact location where the graft was
executed,andwhetherthegraftwasusedonaweight-bearing
surface, where greater substance ﬂaps have a better survival.
In our institution, a great deal of consideration goes to
preparing the wound and oﬀ-loading the ulceration. This is
alsoachievedbyinsuringthatinfectedtissueorexposedbone
(osteomyelitis) is removed. The patient’s nutritional and
vascular status is optimized if inadequate or when peripheral
arterial disease is present. Once this is achieved, the wound
is debrided until a healthy granular base is present. If the
wound bed is deep or the contour uneven, we use NPWT
to bring up an even, granular base. Following this, the
patient is taken to the operating room for STSG application.
Only Puttirutvong [7]a n dR a m a n u j a m[ 8] presented their
harvesting technique in detail. At our institution, a “classical
approach” is utilized with a 0.015 inch thick setting on the
dermatome used to harvest the graft from the lateral thigh
or leg. We traditionally use local anesthetic with epinephrine
in the underlying subcutaneous tissue and mineral oil at the
donor site for ease of dermatome gliding. The donor site
is covered with a nonadherent petroleum gauze dressing.
Then, the graft usually meshed at a 1.5 or 3:1 ratio prior
to application. There are some newer studies that use a
polyurethane membrane over the donor site skin [28]. This
membrane is also used on the recipient site instead of NPWT
and has shown decreased operating room time, no suture
requirement, and maintenance of STSG hydration.
Application of the skin graft, postoperative dressings
and protocol diﬀered amongst the authors, seen in [6–9]
(Table 2). We prefer to use an absorbable suture to ﬁx the
graft suturing from the graft to the recipient site wound4 Plastic Surgery International
Table 2: Postoperative courses.
Lead author Dressings to recipient site Antibiotics Postop Weight bearing 1st dressing change FU appointments
Mahmoud
Paraﬃn gauze, diluted
povidone-iodine- soaked gauze,
sterile gauze and roll bandage
N/A Oﬀ-loading as required post-op day 5
5d a y s ,2w k s ,
3wks,8wks,
monthly
Puttirutvong
Non-adhesive gauze, wet swab
with NSS and mild pressure
outer layer
N/A Weight bearing status
not detailed post-op day 1 N/A
Ramanujam
Bolster dressing: sterile
nonadherent petrolatum gauze,
several sterile plain sponges
moistened in saline attached with
skin staples, short leg
cast/posterior splint
>2wksoralwith
+ wound cultures
Non-weight bearing in
short leg cast or
posterior splint ×
3-4wks
3-4 wks post-op
every 2wks x 2
months, every 3-4
months once
healed
Younes
Sterile nitrofurazone dressing,
gauze, backslap of plaster of Paris
for 1-2wks
N/A Post-op splint × 1-2wks post-op day 3 or 4 N/A
Abbreviations: N/A, not applicable; postop, postoperative; FU, Follow-up wks; weeks, NSS, normal sterile saline.
edges. Following this, we apply a nonadherent dressing atop
the graft followed by NPWT typically set at 75mmHg con-
tinuous pressure. The patient is made non-weight bearing to
thisextremity.Thedonorsitedressingisremovedintwodays
and kept dry. The VAC at the recipient site is taken down ﬁve
days postoperatively. Next, a non-adherent dressing is placed
over the STSG to keep it moist and prevent any shearing. The
minimum follow-up was also not consistent in the research,
ranging from six months to one year. We have found that
the STSG becomes engrafted within two weeks and fully
healed in about four weeks. There are several post-operative
dressings that can be used with a bolster dressing: gauze,
ﬁbrin glue, silicone splints, foams, and other self-adherents.
An important factor is immobilizing the graft to ensure
capillary ingrowth during the ﬁrst 2–5 days of inosculation
[30]. This is diﬃcult on the lower extremity and any area of
uneven, irregular surfaces. Analyzing some of the literature,
there has been several studies comparing the ideal dressing
for both the recipient and donor site. Over eighty articles
are accessible solely analyzing donor site dressings. Studying
the most recent articles, no “best” donor site dressing exists:
“the ideal dressing material for handling of the donor site
is yet to be developed and extensive variability exists in the
management of the STSG donor sites.” [29]. Ironically, the
donor site is the primary cause of pain and distress for
patients. Because of this, more research should be devoted to
ﬁndingtheidealdonorsitedressing.Also,astudycomparing
the location of the donor site would be valuable; for instance,
harvesting skin from a more distal site (lower leg or foot) in
a patient with peripheral neuropathy may be less painful.
The articles in this literature review did not use a
wound VAC to immobilize their STSG. Some more recent
techniques [30–32] have shown success using a wound VAC
to immobilize the graft during the inosculation period,
upwards of 97% [1, 26]. NPWT provides uniform pressure
over the entire grafted area. The pressure is usually set to be
continuous, and normally between 75mmHg to 125mmHg.
The VAC is then typically left in place four to ﬁve days.
It should be noted that none of the articles describe
the importance of optimizing good vascular supply prior to
application. The vascular status must be assessed, especially
if a distal pulse—posterior tibial artery, perforating peroneal
artery, or dorsal pedis artery is not palpable. If a triphasic
wave form is not found with a hand-held doppler, non-
invasive studies are recommended. These authors prefer to
ﬁnd the ankle brachial indexes (ABI) with pulse volume
recordings (PVRs). The vessels media may be calciﬁed
(which can be seen on X-rays—Monckeberg’s sign). This
makes the vessel noncompressible or give an elevated ABI
>1.0. If the ABI is less than 0.90, peripheral artery disease
(PAD) is expected, as seen in Figure 1. If the ABI is less
than 0.40, the disease is severe and vascular intervention is
indicated. PVRs are helpful and complete the ABI exam.
Plethysmography helps gauge the blood ﬂow or perfusion
to the limb without targeting a speciﬁc vessel. If there are
inequalities between contralateral limbs (>20mmHg), or if
there is a large drop in pressure between adjacent cuﬀso n
the ipsilateral limb (>30mmHg), vascular occlusive disease
is expected. If pressures are abnormal, and the waveform has
a short and wide peak, extensive disease is present [33, 34]. If
results are abnormal, a more invasive exam is recommended
like angiography to determine the exact location and severity
of the ischemia and potential revascular procedures.
Along with optimizing vascular status, controlling infec-
tion and creating a healthy wound bed is pertinent prior to
STSG application, as these two factors may be the primary
reason why the diabetic wound is chronic. Wound bed
preparation is a constantly evolving science with a focus
on making a chronic wound acute. It is important to
start with the basics: remove infected, nonviable tissue with
regular debridements & ensure that the wound bed has good
vascular supply to promote a healthy, moist wound bed and
promote epithelial advancement. This is a dynamic process
where all non-viable & infected tissues must be removed and
antibiotic therapy is traditionally started. If osteomyelitis is
suspected (there is exposed bone or the wound probes toPlastic Surgery International 5
ABI < 0.9
severe) diﬀerence
between
contralateral
PVR cuﬀs
gradient
between
consecutive
PVR cuﬀs
Nonpalpable
pulse
>20 mmHg
>30 mmHg
(<0.4 is
Figure 1: Indicators of peripheral artery disease.
Optimize
vascular
supply
Control
infection
Maximize
nutritional
status
Oﬀ-load
pressure
Figure 2: Principle factors in diabetic wound healing.
bone), this must be addressed before the wound is closed.
Twootherfactorstomonitor,andwhichmaycausetheinitial
ulceration are excessive pressure and poor nutritional status.
Figure 2 depicts the principle factors to grant a successful
graft and close a diabetic ulceration.
There are diﬀerent processes to prepare the wound bed
if the bodies natural response is lethargic. This institution
prefers mechanical & surgical debridements prior to grafting
because it is time tested and gives quick results. For patients
withmoreischemicwoundsandthoseforwhichsurgerymay
be less urgent, we turn towards enzymatic or collagen-based
debridements to maintain more healthy tissue. Biologics &
biosurgery are other methods that can be employed, though
not routinely at this institution. There is increased interest
in applying honey to wounds to help stimulate autolytic
debridement [35]. Also, sterile maggots have been used over
eighty years (1931) for successful wound debridement &
preparation [36]. No matter the approach to preparing the
wound bed, basic healing principles must also be ensured for
graft survival and long-term viability.
4. Conclusions
On burn patients, split-thickness skin grafts have upwards
of 100% success rates. There is minimal research available
studying STSGs on diabetic patients. The majority of litera-
ture available on diabetic patients is retrospective reviews or
case studies, which further limits this literature review. Also,
the accessible articles do not mention the vascular status
of the patients, which is often diminished in diabetics; this
is an important factor in wound healing. Infection control,
nutritional status, and pressure oﬀ-loading are pertinent
to treating diabetic wounds and optimizing the recipient
wound bed for STSG survival. Another aspect that was
limited in the revises is the location of the wounds and
graft application. Though wound size is included, depth
and location are lacking in the articles. These factors help
determine which plastic surgery technique can be utilized.
There are better options than STSG for weight-bearing or
plantar surfaces that can resist direct pressure and sheer
forces. Also greater substance ﬂaps should be employed
atop bone and ligamentous and tendinous structures to
prevent adhesions and ultimately graft failure, where STSG
is contraindicated due to avascularity of these tissues.
Despite these limitations, the accessible research [6–27]
demonstrates that split-thickness skin grafting is versatile: it
can be used as the primary modality on the recipient wound,
secondarily as an adjunct to a partially accepted/failed
treatment, or on the donor site of another plastic surgery
modality. When used as the primary closure on optimized
diabetic foot ulcerations, split-thickness skin grafts are 78%
successful at closing 90% of the wound by eight weeks.
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